Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
firmonertinib + anlotinib + chemotherapy
- Development stage
- Unknown
- Lead developer
- Advenchen Laboratories
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Firmonertinib + anlotinib + chemotherapy is an investigational combination regimen being evaluated as neoadjuvant therapy for resectable, EGFR-mutant non-small cell lung cancer (NSCLC). The regimen consists of firmonertinib (brand name Ivesa; formerly furmonertinib), an oral, third-generation, small-molecule EGFR tyrosine kinase inhibitor (TKI); anlotinib, a small-molecule, multi-target TKI that inhibits VEGFR, PDGFR, FGFR, and c-Kit; and platinum-based doublet chemotherapy (such as carboplatin or cisplatin combined with pemetrexed). This combination is being studied in a prospective, multicenter, single-arm, Phase II exploratory clinical trial sponsored by Hubei Cancer Hospital to assess its efficacy and safety in patients with resectable EGFR-mutant NSCLC in the neoadjuvant setting.
- Other names
- firmonertinib combined with anlotinib and chemotherapyfirmonertinib combined with anlotinib and platinum-based doublet chemotherapyfurmonertinib + anlotinib + chemotherapyfurmonertinib combined with anlotinib and chemotherapyfurmonertinib combined with anlotinib and platinum-based doublet chemotherapy
02
Targets
VEGFR-1 (Vascular endothelial growth factor receptor 1)EGFR (Epidermal growth factor receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)PDGFRA (Platelet-derived growth factor receptor alpha)DHFR (Dihydrofolate reductase)VEGFR4 (Vascular endothelial growth factor Receptor-3)FGFR2 (Keratinocyte growth factor receptor)FGFR4 (Fibroblast growth factor receptor 4)DNAFGFR3 (Fibroblast growth factor receptor 3)GART (GAR transformylase)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on firmonertinib + anlotinib + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on firmonertinib + anlotinib + chemotherapy.